Granulomatosis with polyangiitis (Wegener): Clinical aspects and treatment

Autoimmunity Reviews

Volumn 13, Issue 11, 2014, Pages 1121-1125

  Comarmond, Cloé ^a,b,c,d,e   Cacoub, Patrice ^a,b,c,d,e  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

^d CNRS   (France)

^e Sorbonne Université   (France)

Author keywords

ANCA; Characteristics; Granulomatosis with polyangiitis; Treatment

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; SERINE PROTEINASE INHIBITOR;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG DOSE REDUCTION; EPIDEMIOLOGICAL DATA; HUMAN; LOWER RESPIRATORY TRACT; LUNG HEMORRHAGE; LUNG NODULE; MAINTENANCE THERAPY; PATHOGENESIS; PROGNOSIS; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHINORRHEA; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT; WEGENER GRANULOMATOSIS; GRANULOMATOSIS WITH POLYANGIITIS; IMMUNOLOGY; PHENOTYPE;

ADRENAL CORTEX HORMONES; DIAGNOSIS, DIFFERENTIAL; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHENOTYPE; PROGNOSIS;

EID: 84908543178     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.017     Document Type: Review

References (42)

1. Jagiello P., Gross W.L., Epplen J.T. Complex genetics of Wegener granulomatosis. Autoimmun Rev 2005, 4:42-47.
2. Schilder A.M. Wegener's granulomatosis vasculitis and granuloma. Autoimmun Rev 2010, 9:483-487.
3. Mahr A., Guillevin L., Poissonnet M., Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004, 51:92-99.
4. Mohammad A.J., Jacobsson L.T.H., Westman K.W.A., Sturfelt G., Segelmark M. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatol Oxf Engl 2009, 48:1560-1565.
5. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013, 65:1-11.
6. Thai L.-H., Charles P., Resche-Rigon M., Desseaux K., Guillevin L. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 2014, 13:313-318.
7. Noel N., André C., Bengoufa D., Dehoulle C., Mahler M., Limal N., et al. Performance evaluation of three assays for the detection of PR3-ANCA in granulomatosis with polyangiitis in daily practice. Autoimmun Rev 2013, 12:1118-1122.
8. Leavitt R.Y., Fauci A.S., Bloch D.A., Michel B.A., Hunder G.G., Arend W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990, 33:1101-1107.
9. Stegeman C.A., Tervaert J.W., Sluiter W.J., Manson W.L., de Jong P.E., Kallenberg C.G. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994, 120:12-17.
10. Lyons P.A., Rayner T.F., Trivedi S., Holle J.U., Watts R.A., Jayne D.R.W., et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012, 367:214-223.
11. Trimarchi M., Sinico R.A., Teggi R., Bussi M., Specks U., Meroni P.L. Otorhinolaryngological manifestations in granulomatosis with polyangiitis (Wegener's). Autoimmun Rev 2013, 12:501-505.
12. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
13. Daum T.E., Specks U., Colby T.V., Edell E.S., Brutinel M.W., Prakash U.B., et al. Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995, 151:522-526.
14. Little M.A., Nightingale P., Verburgh C.A., Hauser T., De Groot K., Savage C., et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043.
15. Chang D., Wu L., Liu G., Chen M., Kallenberg C.G.M., Zhao M. Re-evaluation of the histopathologic classification of ANCA-associated glomerulonephritis: a study of 121 patients in a single center. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 2012, 27:2343-2349.
16. Dufour J.-F., Le Gallou T., Cordier J.-F., Aumaître O., Pinède L., Aslangul E., et al. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. Medicine (Baltimore) 2012, 91:67-74.
17. Seror R., Mahr A., Ramanoelina J., Pagnoux C., Cohen P., Guillevin L. Central nervous system involvement in Wegener granulomatosis. Medicine (Baltimore) 2006, 85:54-65.
18. Bullen C.L., Liesegang T.J., McDonald T.J., DeRemee R.A. Ocular complications of Wegener's granulomatosis. Ophthalmology 1983, 90:279-290.
19. Leavitt J.A., Butrus S.I. Wegener's granulomatosis presenting as dacryoadenitis. Cornea 1991, 10:542-545.
20. Perry S.R., Rootman J., White V.A. The clinical and pathologic constellation of Wegener granulomatosis of the orbit. Ophthalmology 1997, 104:683-694.
21. Grant S.C., Levy R.D., Venning M.C., Ward C., Brooks N.H. Wegener's granulomatosis and the heart. Br Heart J 1994, 71:82-86.
22. Sarlon G., Durant C., Grandgeorge Y., Bernit E., Veit V., Hamidou M., et al. Cardiac involvement in Wegener's granulomatosis: report of four cases and review of the literature. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne 2010, 31:135-139.
23. Deniz K., Ozşeker H.S., Balas S., Akpýnar E., Sökmensüer C. Intestinal involvement in Wegener's granulomatosis. J Gastrointest Liver Dis JGLD 2007, 16:329-331.
24. Yildirim A.C., Koçak E., Yildiz P., Yildiz M., Karakayali A.Ş., Kaptanoglu B., et al. Multiple intestinal perforation in a patient with Wegener's granulomatosis: a case report and review of the literature. Gastroentérologie Clin Biol 2010, 34:712-715.
25. Merkel P.A., Lo G.H., Holbrook J.T., Tibbs A.K., Allen N.B., Davis J.C., et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005, 142:620-626.
26. Allenbach Y., Seror R., Pagnoux C., Teixeira L., Guilpain P., Guillevin L., et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009, 68:564-567.
27. Holle J.U., Gross W.L., Holl-Ulrich K., Ambrosch P., Noelle B., Both M., et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis 2010, 69:1934-1939.
28. Stone J.H., Wegener's Granulomatosis Etanercept Trial Research Group Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003, 48:2299-2309.
29. Csernok E., Trabandt A., Müller A., Wang G.C., Moosig F., Paulsen J., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999, 42:742-750.
30. Mukhtyar C., Flossmann O., Hellmich B., Bacon P., Cid M., Cohen-Tervaert J.W., et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008, 67:1004-1010.
31. Miloslavsky E.M., Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013, 65:2441-2449.
32. Luqmani R.A., Bacon P.A., Beaman M., Scott D.G., Emery P., Lee S.J., et al. Classical versus non-renal Wegener's granulomatosis. Q J Med 1994, 87:161-167.
33. Berden A.E., Ferrario F., Hagen E.C., Jayne D.R., Jennette J.C., Joh K., et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol JASN 2010, 21:1628-1636.
34. Guillevin L., Pagnoux C., Seror R., Mahr A., Mouthon L., Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore) 2011, 90:19-27.
35. Luqmani R., Suppiah R., Edwards C.J., Phillip R., Maskell J., Culliford D., et al. Mortality in Wegener's granulomatosis: a bimodal pattern. Rheumatol Oxf Engl 2011, 50:697-702.
36. Holle J.U., Gross W.L. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev 2013, 12:483-486.
37. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010, 363:221-232.
38. Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., Hoffman G.S., et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013, 369:417-427.
39. Jayne D.R.W., Gaskin G., Rasmussen N., Abramowicz D., Ferrario F., Guillevin L., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol JASN 2007, 18:2180-2188.
40. Walsh M., Merkel P.A., Peh C.A., Szpirt W., Guillevin L., Pusey C.D., et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. Trials 2013, 14:73.
41. Langford C.A., Monach P.A., Specks U., Seo P., Cuthbertson D., McAlear C.A., et al. An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). Ann Rheum Dis 2014, 73:1376-1379.
42. Pagnoux C., Mahr A., Hamidou M.A., Boffa J.-J., Ruivard M., Ducroix J.-P., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008, 359:2790-2803.